Introduction
Chemotherapy
Reference (year) | Regimen | Number of patients | Median age (years) | CR,% | ORR,% | Median PFS (months) | OS |
---|---|---|---|---|---|---|---|
Rai, 2000 [4] | Chlorambucil | 181 | 62 | 4 | 37 | 14 | Median 56 m |
Fludarabine | 170 | 64 | 20 | 63 | 20 | Median 66 m | |
Eichhorst, 2009 [5] | Chlorambucil | 100 | 70 | 0 | 51 | 18 | Median 64 m |
Fludarabine | 93 | 71 | 7 | 72 | 19 | Median 46 m | |
Knauf, 2009 [7] | Chlorambucil | 157 | 66 | 2 | 31 | 8.3 | NR |
Bendamustine | 162 | 63 | 31 | 68 | 21.6 | NR | |
Eichhorst, 2006 [9] | Fludarabine | 164 | 59 | 7 | 83 | 20 | 81% at 3 y |
FC | 164 | 58 | 24 | 94 | 48 | 80% at 3 y | |
Catovsky, 2007 [10] | Fludarabine | 194 | 64 | 15 | 80 | 23 | 52% at 5 y |
FC | 196 | 65 | 38 | 94 | 43 | 54% at 5 y | |
Chlorambucil | 387 | 65 | 7 | 72 | 20 | 59% at 5 y | |
Flinn, 2007 [11] | Fludarabine | 137 | 61 | 5 | 60 | 19 | 80% at 2 y |
FC | 141 | 61 | 23 | 74 | 32 | 79% at 2 y | |
Robak, 2010 [13] | CC | 192 | 58 | 47 | 88 | 28 | 62.4% at 4 y |
FC | 203 | 59 | 46 | 82 | 27 | 60.6% at 4 y | |
Robak, 2011 [15] | Cladribine | 174 | 61 | 21 | 78 | 27.2 | Median 45 m |
CC | 171 | 62 | 29 | 83 | 22.4 | Median 48 m | |
CMC | 163 | 59 | 36 | 80 | 25.6 | Median 46 m |
Monoclonal antibodies
Rituximab
Reference (year) | Regimen | Phase | Number of patients | Treatment status | CR,% | ORR,% | Median PFS (months) | Median OS (months) |
---|---|---|---|---|---|---|---|---|
Woyach, 2011 [17] | FR (C) | 2 | 51 | Untreated | 47 | 90 | 42 | 85 |
FR (S) | 53 | Untreated | 28 | 77 | ||||
Kay, 2007 [18] | PCR | 2 | 64 | Untreated | 41 | 91 | 32.6 | Not Rep |
Kay, 2010 [19] | PR | 2 | 33 | Untreated | 27 | 76 | 12 | Not Rep |
Reynolds, 2011 [20] | PCR | 3 | 92 | 20% Pretreated | 7 | 49 | NR | NR |
FCR | 92 | 20% Pretreated | 14 | 59 | NR | NR | ||
Wierda, 2011 [21] | FBR | 1/2 | 14 | Untreated | 36 | 93 | Not Rep | Not Rep |
Bosch, 2011 [23] | R-FCM | 2 | 72 | Untreated | 82 | 93 | Not Rep | Not Rep |
Jenke, 2011 [24] | CHOP-R | 2 | 26 | Pretreated, F-ref | 0 | 54 | 11 | 27 |
15 | Pretreated, RT | 7 | 67 | 15 | 27 | |||
15 | Pretreated, AIC | 0 | 82 | 14 | 50 |
Alemtuzumab
Reference (year) | Regimen | Phase | Number of patients | Treatment status | CR,% | ORR,% | Median PFS (months) | Median OS (months) |
---|---|---|---|---|---|---|---|---|
Hillmen, 2007 [25] | Alemtuzumab | 3 | 149 | Untreated | 24 | 83 | 14.6 | NR |
Chlorambucil | 148 | Untreated | 2 | 55 | 11.7 | NR | ||
Gritti, 2012 [27] | Alemtuzumab | 2 | 18 | F-ref | 8 | 44 | 10.3 | 29.1 |
Stilgenbauer, 2011 [28] | AD | 2 | 30 | Untreated, del(17p) | 20 | 97 | 16.9 | >24 , NR |
17 | Relapse, del(17p) | 0 | 76 | 10.4 | 15 | |||
40 | F-ref | 5 | 70 | 8.4 | 12 | |||
Geisler, 2011 [29] | AFC | 3 | 129 | Untreated, high-risk | 57 | 88 | 37 | NR |
FC | 133 | Untreated, high-risk | 45 | 80 | 31 | NR | ||
Badoux, 2011 [30] | CFAR | 2 | 80 | Refractory /relapse | 29 | 65 | 10.6 | N/A |
Zent, 2011 [31] | PAR | 2 | 19 | Refractory /relapse | 32 | 74 | 7 | 23 |
Ofatumumab
Reference (year) | Regimen | Number of patients | Treatment status | CR,% | ORR,% | Median PFS (months) | Median OS (months) |
---|---|---|---|---|---|---|---|
Wierda, 2010 [36] | Ofatumumab | 95 | FA-ref | 0 | 51 | 5.5 | 14.2 |
111 | BF-ref | 2 | 44 | 5.5 | 17.4 | ||
Flinn, 2011 [37] | Ofatumumab | 42 | Untreated | 0 | 44 | NR | NR |
Wierda, 2011 [38] | O-FC (500 mg) | 31 | Untreated | 32 | 77 | NR | NR |
O-FC (1000 mg) | 30 | Untreated | 50 | 73 | NR | NR | |
Shanafelt, 2011 [39] | PCO | 33 | Untreated | 45 | 94 | NR | NR |